<DOC>
	<DOCNO>NCT02349061</DOCNO>
	<brief_summary>The purpose study evaluate efficacy ustekinumab measure reduction disease activity subject active Active Systemic Lupus Erythematosus ( SLE - chronic disorder connective tissue skin rash , arthritis , kidney problem , anemia , among problem ) .</brief_summary>
	<brief_title>A Phase 2a , Efficacy Safety Study Ustekinumab Systemic Lupus Erythematosus</brief_title>
	<detailed_description>A multicenter ( one medical research center involve study ) , randomize ( study drug assign chance ) , double-blind ( neither Investigator participant know study drug ) , placebo-controlled , proof-of-concept study ustekinumab participant active systemic lupus erythematosus . Participants screen achieve inclusion criterion none exclusion criterion receive either ustekinumab placebo along concomitant background medicine . Participants primarily assess response use Systemic Lupus Erythematosus Response Index 2000 ( SRI-4 ) . Participants ' safety assess throughout study .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Subjects must document medical history meet SLICC classification criterion SLE minimum 3 month prior first dose At least 1 welldocumented ( subject file , refer physician letter , laboratory result ) , unequivocally positive , documented test autoantibody medical history include either follow : ANA , and/or antidsDNA antibody , and/or antiSmith antibody At least 1 unequivocally positive autoantibody test include ANA and/or antidsDNA antibody and/or antiSmith antibody detect screen At least 1 BILAG A and/or 2 BILAG B domain score observe screen prior first administration study agent Demonstrate active disease base SLEDAI2K score great equal ( &gt; = ) 6 observe screening assess approximately 2 6 week prior randomization . Must also SLEDAI2K score &gt; = 4 clinical feature ( ie , SLEDAI exclude laboratory result ) Week 0 prior first administration study agent Have inflammatory disease might confound evaluation efficacy , include limited rheumatoid arthritis ( RA ) , psoriatic arthritis ( PsA ) , RA/lupus overlap , psoriasis active Lyme disease Are pregnant , nursing , plan pregnancy father child enrol study within 4 month receive last administration study agent Have receive systemic topical cream/ointment preparation cyclosporine A systemic immunomodulatory agent describe inclusion criterion within past 3 month prior first administration study agent Have receive single B cell target agent within 3 month prior first study agent administration ; receive 1 previous B cell target therapy include belimumab epratuzamab within 6 month prior first administration study agent ; receive B cell deplete therapy ( eg , rituximab ) within 12 month prior first administration study agent evidence continue Bcell depletion follow therapy Have ever receive ustekinumab Participant history malignancy within 5 year screen ( exception squamous basal cell carcinoma skin treat evidence recurrence least 3 month first study agent administration carcinoma situ cervix surgically cure )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Ustekinumab</keyword>
</DOC>